Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Phase 3

Completed

Conditions: T-Cell Lymphoma
Anaplastic Large-Cell Lymphoma
Non-Hodgkin Lymphoma

Interventions: Drug: doxorubicin
Drug: brentuximab vedotin
Drug: prednisone
Drug: vincristine
Drug: cyclophosphamide

First Posted Date: 2013-01-28

Last Posted Date: 2021-11-30

Lead Sponsor: Seagen Inc.

Target Recruit Count: 452

Registration Number: NCT01777152

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States
🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

and more 141 locations

Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: AIDS-related Diffuse Mixed Cell Lymphoma
AIDS-related Peripheral/Systemic Lymphoma
AIDS-related Lymphoblastic Lymphoma
AIDS-related Small Noncleaved Cell Lymphoma
Stage IV AIDS-related Lymphoma
AIDS-related Diffuse Large Cell Lymphoma
Stage III AIDS-related Lymphoma
AIDS-related Diffuse Small Cleaved Cell Lymphoma
AIDS-related Immunoblastic Large Cell Lymphoma

Interventions: Drug: cyclophosphamide
Drug: lomustine
Drug: etoposide
Drug: doxorubicin hydrochloride
Drug: vincristine sulfate
Drug: procarbazine hydrochloride
Drug: prednisone
Other: laboratory biomarker analysis

First Posted Date: 2013-01-25

Last Posted Date: 2022-10-10

Lead Sponsor: AIDS Malignancy Consortium

Target Recruit Count: 7

Registration Number: NCT01775475

Locations: 🇿🇼
University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
🇰🇪
Moi Teaching and Referral Hospital, Eldoret, Kenya

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies

Early Phase 1

Completed

Conditions: Diffuse Large B Cell Lymphoma
Primary Mediastinal (Thymic) Large B-cell Lymphoma
Post Transplant Lymphoproliferative Disorder

Interventions: Drug: DA-EPOCH-R for DLBCL, PTLD, AND PMBCL
Drug: Methotrexate
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Prednisone
Drug: G-CSF

First Posted Date: 2013-01-04

Last Posted Date: 2024-02-21

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 4

Registration Number: NCT01760226

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Glucocorticoids in Patients With IgG4-RD

Phase 2

Conditions: IgG4-related Disease

Interventions: Drug: Prednisone

First Posted Date: 2013-01-01

Last Posted Date: 2013-01-01

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 40

Registration Number: NCT01758393

Locations: 🇨🇳
Deptment of Rheumatology, Peking Union Medical College Hospital, Beijing, Beijing, China

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer

Phase 2

Withdrawn

Conditions: Castrate-resistant Metastatic Prostate Cancer

Interventions: Drug: Cabazitaxel
Drug: Prednisone
Drug: Granulocyte colony-stimulating factor (G-CSF)

First Posted Date: 2012-12-17

Last Posted Date: 2013-10-16

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT01750866

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Phase 2

Terminated

Conditions: T-cell Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Etoposide
Drug: Prednisone
Drug: Filgrastim
Drug: Plerixafor
Procedure: Stem Cell Collection
Drug: Palifermin
Drug: Gemcitabine
Drug: Busulfan
Drug: Melphalan
Procedure: Stem Cell Transplant

First Posted Date: 2012-12-10

Last Posted Date: 2023-01-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01746173

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

BKM120+Abiraterone Acetate for Metastatic CRPC

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: BKM120
Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2012-12-05

Last Posted Date: 2019-02-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 4

Registration Number: NCT01741753

Locations: 🇺🇸
Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Castrate-resistant Prostate Cancer

Interventions: Drug: BEZ235
Drug: Prednisone
Drug: Abiraterone acetate

First Posted Date: 2012-10-31

Last Posted Date: 2018-03-27

Lead Sponsor: Charles Ryan

Target Recruit Count: 6

Registration Number: NCT01717898

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2

Completed

Conditions: Prostate Cancer Metastatic

Interventions: Drug: DOCETAXEL (XRP6976)
Drug: CABAZITAXEL (XRP6258)
Drug: Prednisone

First Posted Date: 2012-10-31

Last Posted Date: 2017-11-20

Lead Sponsor: Sanofi

Target Recruit Count: 63

Registration Number: NCT01718353

Locations: 🇺🇸
Investigational Site Number 840017, Rockville, Maryland, United States
🇺🇸
Investigational Site Number 840003, Birmingham, Alabama, United States
🇺🇸
Investigational Site Number 840002, Baltimore, Maryland, United States

and more 16 locations

Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Abiraterone acetate
Drug: Androgen deprivation
Radiation: Radiation Therapy
Drug: Prednisone

First Posted Date: 2012-10-30

Last Posted Date: 2022-10-10

Lead Sponsor: Duke University

Target Recruit Count: 37

Registration Number: NCT01717053

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Durham Regional Hospital, Durham, North Carolina, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy